Department of Surgery and Research Unit, Rambam Medical Center, 31096, Haifa, Israel.
World J Urol. 2013 Dec;31(6):1541-5. doi: 10.1007/s00345-013-1043-1. Epub 2013 Feb 22.
NGAL and KIM-1 are suggested to play a key role in the carcinogenesis and progression of renal cell carcinoma. Attention is currently focused on the potential use of the urinary level of NGAL and KIM-1(uNGAL and uKIM-1, respectively) in making an early diagnosis, establishing a prognosis and determination of the histologic characteristics.
Forty-six patients underwent surgical treatment for renal lesions (n = 37) and for non-functioning kidney (n = 9). uNGAL and uKIM-1 levels were evaluated for clear cell, papillary and chromophobe subtypes of renal cancer patient and also for the control patients. The concentrations were determined by ELISA.
uNGAL and uKIM-1 in the control group were not significantly different from those of the patients with kidney cancer. There was no association between tumor size or histologic grade and the uNGAL and uKIM-1 levels. All patients with papillary type RCC had KIM-1 level below 2 ng/mgUcr and uNGAL concentration above 50 ng/mgUcr. Using the same threshold values enables prediction of 100% of patients with chromophobe subtype; 91.6% of the patients with clear cell histology have uNGAL concentration below 50 ng/mgUcr and KIM-1 concentration below 5 ng/mgUce.
Combined analysis of uNGAL and uKIM-1 allowed high prediction rate of the histologic subtype of the radiographic-detected masses among cases with kidney cancer. These biomarkers may enable to select the proper therapeutic agents in cases with metastatic disease without the need of pretreatment biopsy.
中性粒细胞明胶酶相关脂质运载蛋白(NGAL)和肾损伤分子-1(KIM-1)被认为在肾细胞癌的发生和进展中起着关键作用。目前人们关注的是尿 NGAL(uNGAL)和尿 KIM-1(uKIM-1)的水平在早期诊断、预后判断和组织学特征确定方面的潜在应用。
46 例接受手术治疗的肾脏病变患者(n = 37)和无功能肾脏患者(n = 9),分别检测 uNGAL 和 uKIM-1 水平。用酶联免疫吸附试验(ELISA)法检测尿 NGAL 和 uKIM-1 的浓度。
对照组 uNGAL 和 uKIM-1 与肾癌患者无显著差异。肿瘤大小或组织学分级与 uNGAL 和 uKIM-1 水平无相关性。所有肾透明细胞癌患者的 KIM-1 水平均低于 2 ng/mgUcr,uNGAL 浓度均高于 50 ng/mgUcr。采用相同的阈值值可以预测 100%的嫌色细胞亚型患者;91.6%的肾透明细胞癌患者 uNGAL 浓度低于 50 ng/mgUcr,KIM-1 浓度低于 5 ng/mgUcr。
联合分析 uNGAL 和 uKIM-1 可提高对肾癌患者影像学检测到的肿块组织学亚型的预测率。这些生物标志物可能使我们能够在不需要预处理活检的情况下,为转移性疾病患者选择合适的治疗药物。